News >

Acalabrutinib Improves PFS in Relapsed/Refractory CLL

Gina Columbus @ginacolumbusonc
Published: Tuesday, May 07, 2019

Jose Baselga, MD

José Baselga, MD

Acalabrutinib (Calquence) monotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with the combination of rituximab (Rituxan) and either idelalisib (Zydelig) or bendamustine in patients with previously treated chronic lymphocytic leukemia (CLL), meeting the primary endpoint of the phase III ASCEND trial (NCT02970318).1

 

References

  1. Calquence Phase III ASCEND Trial Met Primary Endpoint at Interim Analysis in Relapsed or Refractory Chronic Lymphocytic Leukemia and Will Stop Early. AstraZeneca. Published May 7, 2019. https://bit.ly/2H1bNJY. Accessed May 7, 2019.
  2. Sun CC, Nierman P, Ahn IE, et al. Acalabrutinib in patients with relapsed/refractory (R/R) and high-risk, treatment-naive (TN) chronic lymphocytic leukemia (CLL). Blood. 2018;132:4424. doi: 10.1182/blood-2018-99-110395.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x